Showing 4701-4710 of 5623 results for "".
- Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan in Patients with Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-late-breaking-presentation-of-targeted-c3-therapy-pegcetacoplan-in-patients-with-geographic-atrophy-ga/2478309/Apellis Pharmaceuticals announced that a post hoc analysis of the phase 2 FILLY study investigating intravitreal pegcetacoplan (APL-2) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) has been accepted as a late-breaking oral presentation by EURETIN
- Moody’s: Hospital Financial Outlook Worse as COVID-19 Relief Funds Start to Dwindlehttps://modernod.com/news/moodys-hospital-financial-outlook-worse-as-covid-19-relief-funds-start-to-dwindle/2478308/For-profit hospitals are expected to see a financial decline over the next 12 to 18 months as federal relief funds that shored up revenue losses due to COVID-19 start to wane, a recent analysis from Moody’s said, according to a FierceHealthcare
- Rayner to Launch RayOne EMV Enhanced Monofocal IOLhttps://modernod.com/news/rayner-to-launch-rayone-emv-enhanced-monofocal-iol/2478303/Rayner has announced the upcoming European launch of RayOne EMV, a new fully preloaded non-diffractive IOL designed to enhance patient outcomes achieved with monovision. Developed in collaboration with Professor Graham Barrett, president of the Australasian Society of Cata
- Biomarker Indicating Neurodegeneration Identified in the Eyehttps://modernod.com/news/biomarker-indicating-neurodegeneration-identified-in-the-eye/2478302/A new study led by Boston Medical Center researchers indicates a well-known biomarker that serves as a marker for earlier diagnosis of neurodegenerative diseases is now detectable in the eye. Neurofilament light chain, a protein previously detected in cerebrospinal fluid and blood that is
- Liminal BioSciences Provides Update on Progress on BLA for Ryplazim (Plasminogen)https://modernod.com/news/liminal-biosciences-provides-update-on-progress-on-bla-for-ryplazim-plasminogen/2478301/Liminal BioSciences announced that the FDA acknowledged receipt of the resubmission of the Biologic License Application (BLA) for Ryplazim (plasminogen) for the treatment of clinical signs and symptoms associated with congenital plasminogen deficiency (C-PLGD) in pediatrics and adults. The
- Roche’s Actemra/RoActemra Cuts Need for Ventilator Use in COVID-19 Pneumoniahttps://modernod.com/news/roches-actemra-roactemra-cuts-need-for-ventilator-use-in-covid-19-pneumonia/2478299/Roche announced results from the EMPACTA study on Friday, showing that patients with COVID-19-associated pneumonia who had Actemra/RoActemra (tocilizumab) added to standard care were 44% less likely to progress to mechanical ventilation or death compared to placebo plus standard care, meeting the
- Bausch Health Acquires Option To Purchase Ophthalmology Assets Of Allegro Ophthalmicshttps://modernod.com/news/bausch-health-to-acquire-option-to-purchase-all-ophthalmology-assets-of-allegro-ophthalmics/2478300/Bausch Health has entered into an agreement to acquire an option to purchase all ophthalmology assets of Allegro Ophthalmics, including global rights for risuteganib (Luminate)1, Allegro’s lead investigational compound in retina. Full financial terms of the deal were not d
- Neuro-Optometric Rehabilitation Association Announces Appointments of New Executive and Advisory Board Officershttps://modernod.com/news/neuro-optometric-rehabilitation-association-announces-appointments-of-new-executive-and-advisory-board-officers/2478297/The Neuro-Optometric Rehabilitation Association (NORA) announced the appointments of its new executive and advisory board members. DeAnn Fitzgerald, OD, assumes the position of President, succeeding Susan Daniel, OD, who now joins the NORA Advisory Board. Dr. Fitzgerald has been providing
- Nicox Announces Senior Management Changehttps://modernod.com/news/nicox-announces-senior-management-change/2478295/Nicox announced that Tomas Navratil, PhD, Executive Vice President & Head of Research & Development of the Nicox Group and General Manager of Nicox Ophthalmics, will be leaving the company on October 16, 2020 to pursue other opportunities. Nicox has initiated a search for a successor. In
- MetLife to Acquire Versant Health, Owner of Davis Vision and Superior Visionhttps://modernod.com/news/metlife-to-acquire-versant-health-owner-of-davis-vision-and-superior-vision/2478292/MetLife announced it has entered into a definitive agreement to acquire Versant Health from an investor group led by Centerbridge Partners and including FFL Partners for approximately $1.675 billion in an all-cash transaction. Versant Health owns the marketplace brands Davis Vision and Superior V